Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

The European medical isotope programme: Production of high purity isotopes by mass separation

Descripción del proyecto

Infraestructura europea para la producción de radionucleidos

La medicina nuclear utiliza moléculas radioactivas, llamadas radiofármacos, cuya radiación ofrece información diagnóstica y trata varias afecciones médicas, incluido el cáncer. Los elementos radioactivos, conocidos como radionucleidos, poseen un excedente de energía que se libera mediante diferentes tipos de desintegración radiactiva. El objetivo principal del proyecto PRISMAP, financiado con fondos europeos, es establecer una estructura europea y un punto de entrada común para los investigadores y físicos de este campo. El consorcio creará una fuente sostenible de radionucleidos no convencionales de alta pureza para desarrollos en medicina, así como protocolos y servicios para la industria farmacéutica y el sector sanitario, en un programa europeo de radionucleidos médicos sostenible.

Objetivo

PRISMAP - The European medical isotope programme: Production of high purity isotopes by mass separation proposes to federate a consortium of the key European intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical research institutes and hospitals active in the translation of the emerging radionuclides into medical diagnosis and treatment. PRISMAP will create a single-entry point for a fragmented user community distributed amongst universities, research centres, industry and hospitals, in a similar way as the National Isotope Development Center NIDC supported by the Department of Energy (DOE) has provided radionuclide sources for users in the USA. PRISMAP brings together a consortium of 23 beneficiaries from 13 countries, one European Research Laboratory and an International Organisation. It further receives support of leading associations and institutions in the field such as the European Association of Nuclear Medicine (EANM) and the International Atomic Energy Agency (IAEA). Our main goal is to provide a sustainable source of high purity grade new radionuclides for medicine, involving from the onset upcoming major European infrastructures, to provide a single-entry point for all researchers active in this field including SMEs, global pharma, nuclear centres, hospitals and universities, using standardised access procedures. The new isotope enrichment and standardisation techniques triggered in PRISMAP will expand our services and provide them to yet unreachable remote European laboratories. PRISMAP thus strives to create a paradigm shift in the early phase research on radiopharmaceuticals, targeted drugs for cancer – one of the major diseases in Europe - theranostics and personalised medicine, shaping the European isotope landmark as a gold standard to accelerate the development of the pharma industry and ultimately of a better healthcare for the improvement of our citizens’ life.

Convocatoria de propuestas

H2020-INFRAIA-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-INFRAIA-2020-1

Régimen de financiación

RIA - Research and Innovation action

Coordinador

ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE
Aportación neta de la UEn
€ 1 032 220,00
Dirección
ESPLANADE DES PARTICULES 1 PARCELLE 11482 DE MEYRIN BATIMENT CADASTRAL 1046
1211 Meyrin
Suiza

Ver en el mapa

Región
Schweiz/Suisse/Svizzera Région lémanique Genève
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 1 032 220,00

Participantes (22)